Lynda M. Vrooman, MD
Medical Director, David B. Perini Jr. Quality of Life Clinic; Clinical Program Leader, Pediatric Survivorship Program; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Lynda M. Vrooman, MD
Medical Director, David B. Perini Jr. Quality of Life Clinic; Clinical Program Leader, Pediatric Survivorship Program; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Yale University
New Haven
CT
Medical School
Harvard Medical School
Boston
MA
Internship
Pediatrics
Boston Combined Residency Program (BCRP)
Boston
MA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Boston Children's Hospital / Dana-Farber Cancer Institute
Boston
MA
Certifications
American Board of Pediatrics (Hematology-Oncology)
Publications
Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. View Abstract
Help Navigate the Process: Early Information and Communication About Late Effects of Pediatric and Adolescent Cancer. View Abstract
Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors. View Abstract
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. View Abstract
Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. View Abstract
Cancer survivorship programs at the Dana-Farber Cancer Institute. View Abstract
Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review. View Abstract
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. View Abstract
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. View Abstract
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. View Abstract
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. View Abstract
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. View Abstract
Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. View Abstract
Predicting chronic morbidity in childhood cancer survivors. View Abstract
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. View Abstract
Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. View Abstract
Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. View Abstract
Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia. View Abstract
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. View Abstract
Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. View Abstract
Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. View Abstract
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. View Abstract
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. View Abstract
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. View Abstract
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. View Abstract
Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. View Abstract
Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic. View Abstract
Corrigendum. View Abstract
Risk factors for steroid-induced affective disorder in children with leukemia. View Abstract
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. View Abstract
Long-Term Psychosocial Well-Being and Quality of Life Among Childhood Cancer Survivors Who Developed a Subsequent Malignant Neoplasm. View Abstract
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. View Abstract
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. View Abstract
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. View Abstract
Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. View Abstract
A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. View Abstract
Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. View Abstract
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. View Abstract
Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. View Abstract
Adapted Delivery of Cognitive-Behavioral Treatment for Insomnia in Adolescent and Young Adult Cancer Survivors: A Pilot Study. View Abstract
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. View Abstract
Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. View Abstract
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. View Abstract
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. View Abstract
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. View Abstract
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. View Abstract
25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. View Abstract
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. View Abstract
Health status of the oldest adult survivors of cancer during childhood. View Abstract
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. View Abstract
Childhood acute lymphoblastic leukemia: update on prognostic factors. View Abstract
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. View Abstract